JP2013523821A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523821A5
JP2013523821A5 JP2013503845A JP2013503845A JP2013523821A5 JP 2013523821 A5 JP2013523821 A5 JP 2013523821A5 JP 2013503845 A JP2013503845 A JP 2013503845A JP 2013503845 A JP2013503845 A JP 2013503845A JP 2013523821 A5 JP2013523821 A5 JP 2013523821A5
Authority
JP
Japan
Prior art keywords
antihypertensive agent
implant
timolol
antihypertensive
intraocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013503845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523821A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/031265 external-priority patent/WO2011127064A2/en
Publication of JP2013523821A publication Critical patent/JP2013523821A/ja
Publication of JP2013523821A5 publication Critical patent/JP2013523821A5/ja
Pending legal-status Critical Current

Links

JP2013503845A 2010-04-06 2011-04-05 前房内薬剤送達のための徐放性リザーバーインプラント Pending JP2013523821A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32142210P 2010-04-06 2010-04-06
US61/321,422 2010-04-06
PCT/US2011/031265 WO2011127064A2 (en) 2010-04-06 2011-04-05 Sustained-release reservoir implants for intracameral drug delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015090706A Division JP2015166361A (ja) 2010-04-06 2015-04-27 前房内薬剤送達のための徐放性リザーバーインプラント

Publications (2)

Publication Number Publication Date
JP2013523821A JP2013523821A (ja) 2013-06-17
JP2013523821A5 true JP2013523821A5 (cg-RX-API-DMAC7.html) 2014-05-08

Family

ID=44065364

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013503845A Pending JP2013523821A (ja) 2010-04-06 2011-04-05 前房内薬剤送達のための徐放性リザーバーインプラント
JP2015090706A Pending JP2015166361A (ja) 2010-04-06 2015-04-27 前房内薬剤送達のための徐放性リザーバーインプラント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015090706A Pending JP2015166361A (ja) 2010-04-06 2015-04-27 前房内薬剤送達のための徐放性リザーバーインプラント

Country Status (10)

Country Link
US (3) US20130017243A1 (cg-RX-API-DMAC7.html)
EP (1) EP2555749B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013523821A (cg-RX-API-DMAC7.html)
KR (1) KR20130086131A (cg-RX-API-DMAC7.html)
CN (1) CN102905688B (cg-RX-API-DMAC7.html)
AU (1) AU2011237788A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012025581A2 (cg-RX-API-DMAC7.html)
CA (1) CA2795706A1 (cg-RX-API-DMAC7.html)
RU (1) RU2012146630A (cg-RX-API-DMAC7.html)
WO (1) WO2011127064A2 (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションDose Medical Corporation 薬剤溶出眼内インプラント
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
JP2013526572A (ja) 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド 眼治療薬の送達のための薬物送達装置
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
EP3494959A3 (en) 2011-04-29 2019-09-11 Allergan, Inc. Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2014120866A1 (en) 2013-01-31 2014-08-07 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure or glaucoma
EP2956096A1 (en) * 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
ES2751681T3 (es) * 2013-03-15 2020-04-01 Allergan Inc Implante intraocular que contiene prostamida
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
AU2014350095B9 (en) * 2013-11-14 2019-09-12 Eyed Pharma Eye device
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10507101B2 (en) 2014-10-13 2019-12-17 W. L. Gore & Associates, Inc. Valved conduit
BR112017007942A2 (pt) * 2014-10-30 2017-12-19 Textile Based Delivery Inc sistemas de liberação
CN104587850A (zh) * 2015-01-11 2015-05-06 王丽莉 一种聚偏氟乙烯中空纤维膜的制备方法
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
RU2620249C1 (ru) * 2015-12-17 2017-05-23 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Многослойный биодеградируемый глазной имплантат с дозированным высвобождением лекарственного вещества и способ его изготовления
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
KR102814241B1 (ko) 2016-09-23 2025-05-29 인셉트, 엘엘씨 전안방내 약물 전달 데포
EP3518844A4 (en) * 2016-09-30 2020-05-27 Lynthera Corporation HIGH PRECISION DRUG DELIVERY THROUGH A DUAL DOMAIN EYE DEVICE
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US11406533B2 (en) 2017-03-17 2022-08-09 W. L. Gore & Associates, Inc. Integrated aqueous shunt for glaucoma treatment
JP7770768B6 (ja) * 2017-10-13 2025-12-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 繊毛病に関連する疾患の治療方法
RU185437U1 (ru) * 2018-04-12 2018-12-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" Устройство для герметизации капсул алюминиевых
EP3793537A1 (en) * 2018-05-16 2021-03-24 Spirox, Inc. Allergic rhinitis drug delivery implant
EP3843676A1 (en) 2018-08-29 2021-07-07 W.L. Gore & Associates, Inc. Drug therapy delivery systems and methods
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11975087B2 (en) * 2020-03-30 2024-05-07 Colgate-Palmolive Company Sulfate-free personal care compositions and methods for preventing and treating pollution damage to skin
EP4021389A1 (en) 2020-03-30 2022-07-06 Colgate-Palmolive Company Personal care compositions
WO2021247690A1 (en) * 2020-06-03 2021-12-09 Glaukos Corporation Rho kinase inhibitor releasing implants and related methods of use
US20230338278A1 (en) * 2020-09-17 2023-10-26 The University Of North Carolina At Chapel Hill Methods, Systems and Devices for Post-Fabrication Drug Loading
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
US12527691B2 (en) 2021-11-05 2026-01-20 W. L. Gore & Associates, Inc. Fluid drainage devices, systems, and methods
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物
USD1137672S1 (en) 2024-08-27 2026-07-28 Glaukos Corporation Drug eluting ocular implant

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
TR200201047T2 (tr) * 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
BR0309844A (pt) * 2002-05-07 2005-02-15 Control Delivery Sys Inc Processos para formação de um dispositivo para a distribuição de droga
MXPA05007719A (es) * 2003-01-24 2005-09-30 Control Delivery Sys Inc Dispositivo de liberacion sostenida y metodo para la administracion ocular de agentes adrenergicos.
BRPI0406858A (pt) * 2003-01-24 2006-01-03 Control Delivery Sys Inc Liberação controlada de agentes altamente solúveis
PL1696822T3 (pl) * 2003-11-13 2010-08-31 Psivida Inc Wstrzykiwane implanty o opóźnionym wydzielaniu mające matrycę rdzenia i powłokę podatne na erozję biologiczną
EP1706095B1 (en) * 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
CA2624174A1 (en) * 2005-09-28 2007-04-05 The Trustees Of The University Of Pennsylvania Self-assembled biodegradable polymersomes
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
US8231892B2 (en) * 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20080299176A1 (en) * 2007-05-30 2008-12-04 Yu-Chin Lai Drug delivery device comprising crosslinked polyurethane-siloxane-containing copolymers
AU2008300013A1 (en) * 2007-09-07 2009-03-19 Qlt Inc. Drug cores for sustained release of therapeutic agents
US20120245505A1 (en) * 2009-12-16 2012-09-27 Robinson Michael R Intracameral devices for sustained delivery

Similar Documents

Publication Publication Date Title
JP5696121B2 (ja) α−2アドレナリン受容体アゴニスト含有生分解性眼内インプラント
JP6100782B2 (ja) 緑内障および高眼圧症を治療するための活性剤の徐放送達
EP2555749B1 (en) Sustained-release reservoir implants for intracameral drug delivery
JP5580832B2 (ja) 生分解性α−2アゴニストポリマー性インプラントおよびその治療用途
CN110302138B (zh) 含前列腺酰胺的眼内植入物及其使用方法
CN105916509B (zh) 用于眼科应用和/或其它应用的组合物以及方法
CN106604695B (zh) 用于在眼中实现持续药物释放的方法和生物相容性组合物
JP7636334B2 (ja) 治療物質の眼投与のための薬物送達組成物及びその使用法
RU2013102030A (ru) Композиции наноструктурированного апрепитанта, способ их получения и содержащие их фармацевтические композиции
JP2017526655A5 (cg-RX-API-DMAC7.html)
JP2013542239A5 (cg-RX-API-DMAC7.html)
TW200400055A (en) Ophthalmic formulation with novel gum composition
JP2004528267A (ja) 選択的シクロオキシゲナーゼ−2阻害性薬物の眼処方
JP2007535563A (ja) レチノイド含有徐放性薬剤送達システム、ならびに関連する製造法
JP2010513555A (ja) 眼内使用のための環状脂質インプラントの製造法
JP2016513109A (ja) 持続型薬物送達インプラント
TW201034645A (en) Peri-corneal drug delivery device
WO2021262645A1 (en) Redox-responsive nanoparticle compositions for ocular delivery of therapeutics
SG194182A1 (en) Pharmaceutical preparation
WO2019200181A1 (en) Methods and compositions for sustained release microparticles for ocular drug delivery
JP2013534527A5 (cg-RX-API-DMAC7.html)
JP2014515383A5 (cg-RX-API-DMAC7.html)
TW201821086A (zh) 微小rna-195局部用製劑及其用途
JP6213560B2 (ja) 薬剤送達システムならびに開放隅角緑内障および高眼圧症を治療する方法
JP2013510845A5 (cg-RX-API-DMAC7.html)